Results 11 to 20 of about 1,291,893 (344)

Rubella arthritis and rheumatoid arthritis [PDF]

open access: yesArthritis & Rheumatism, 1962
AbstractFourteen cases of rubella arthritis were followed between 2 and 5 years after the attack. All were women. None showed any clinical manifestation suggesting rheumatoid disease over this follow‐up period nor was there a positive reactor using the englobulin sensitized sheep cell agglutination method.
T G, KANTOR, M, TANNER
openaire   +2 more sources

Effect of Immunosuppressive or Immunomodulatory Agents on Severe COVID‐19 Outcomes: A Population‐Based Cohort Study

open access: yesACR Open Rheumatology, 2023
Objective We estimated the association between immunosuppressive and immunomodulatory agent (IIA) exposure and severe COVID‐19 outcomes in a population‐based cohort study.
Shelby Marozoff   +14 more
doaj   +1 more source

Treatment recommendations for psoriatic arthritis [PDF]

open access: yes, 2008
Objective: To develop comprehensive recommendations for the treatment of the various clinical manifestations of psoriatic arthritis (PsA) based on evidence obtained from a systematic review of the literature and from consensus opinion.
Gladman, D.D.   +39 more
core   +1 more source

Severe COVID-19 outcomes among patients with autoimmune rheumatic diseases or transplantation: a population-based matched cohort study

open access: yesBMJ Open, 2022
Objectives To assess the risk of severe COVID-19 outcomes in patients with autoimmune rheumatic diseases (ARDs) and transplant recipients compared with matched general population comparators.Design Population-based matched cohort study using ...
John Esdaile   +7 more
doaj   +1 more source

Arthritis and disability [PDF]

open access: yes, 2014
Executive summary: Arthritis Australia commissioned the Social Policy Research Centre (SPRC) at UNSW Australia to carry out research on the lived experience of people with arthritis related conditions.
Shona Bates   +9 more
core   +2 more sources

Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions

open access: yesAnnals of the Rheumatic Diseases, 2012
Background Since approval of tocilizumab (TCZ) for treatment of rheumatoid arthritis (RA) and juvenile idiopathic arthritis (JIA), interleukin 6 (IL-6) pathway inhibition was evaluated in trials of TCZ and other agents targeting the IL-6 receptor and ...
J. Smolen   +34 more
semanticscholar   +1 more source

Management of Rheumatoid Arthritis: An Overview

open access: yesCells, 2021
Rheumatoid arthritis (RA) is a multifactorial autoimmune disease of unknown etiology, primarily affecting the joints, then extra-articular manifestations can occur.
A. Radu, S. Bungău
semanticscholar   +1 more source

Advanced application of stimuli-responsive drug delivery system for inflammatory arthritis treatment

open access: yesMaterials Today Bio, 2022
Inflammatory arthritis is a major cause of disability in the elderly. This condition causes joint pain, loss of function, and deterioration of quality of life, mainly due to osteoarthritis (OA) and rheumatoid arthritis (RA).
Mi Zhang   +5 more
semanticscholar   +1 more source

2021 American College of Rheumatology Guideline for the Treatment of Juvenile Idiopathic Arthritis: Therapeutic Approaches for Oligoarthritis, Temporomandibular Joint Arthritis, and Systemic Juvenile Idiopathic Arthritis

open access: yesArthritis care & research, 2022
To provide updated guidelines for pharmacologic management of juvenile idiopathic arthritis (JIA), focusing on treatment of oligoarthritis, temporomandibular joint (TMJ) arthritis, and systemic JIA with and without macrophage activation syndrome ...
K. Onel   +36 more
semanticscholar   +1 more source

Home - About - Disclaimer - Privacy